Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial - Report - MDSpire
Advertisement
Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial
Phase 2 Trial of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis
Overview
HS-20137, a novel IL-23p19 monoclonal antibody, demonstrated significant efficacy and a favorable safety profile in Chinese patients with moderate-to-severe psoriasis over 52 weeks. The treatment improved psoriatic lesions and quality of life, supporting its potential as a competitive therapeutic option.
Background
Psoriasis is a chronic immune-mediated inflammatory disease affecting millions globally, including nearly 6.5 million in China. Moderate-to-severe plaque psoriasis requires systemic treatment, with biologics targeting IL-23 showing promising efficacy and convenient dosing. HS-20137 is a novel humanized monoclonal antibody targeting IL-23p19, designed to improve long-term disease control with fewer injections compared to other biologics.
Data Highlights
Endpoint
HS-20137 100 mg Q8W
HS-20137 200 mg Q8W
HS-20137 200 mg Q12W
Placebo
PASI 90 at Week 16
Significantly higher than placebo
Significantly higher than placebo
Significantly higher than placebo
Lowest response rate
PASI 75 and PASI 100
Improved over time
Improved over time
Improved over time
Minimal improvement
IGA 0/1 Achievement
Increased proportion
Increased proportion
Increased proportion
Low proportion
DLQI Score Change
Improved quality of life
Improved quality of life
Improved quality of life
No significant change
Safety Profile
Excellent, no serious adverse events
Excellent, no serious adverse events
Excellent, no serious adverse events
Not applicable
Key Findings
HS-20137 significantly improved PASI 90 response rates at week 16 compared to placebo.
All dosing regimens (100 mg Q8W, 200 mg Q8W, 200 mg Q12W) showed sustained efficacy through 52 weeks.
Patients experienced improvements in Investigator Global Assessment scores and Dermatology Life Quality Index.
The safety profile was favorable with no serious adverse events reported during the study.
Placebo patients crossed over to HS-20137 also showed clinical improvement.
HS-20137’s dosing schedule offers convenience with less frequent injections compared to other biologics.
Clinical Implications
HS-20137 represents a promising treatment for moderate-to-severe plaque psoriasis in Chinese patients, offering significant skin clearance and quality of life improvements with a convenient dosing regimen. Its favorable safety profile supports long-term use, making it a potential competitive option among IL-23 inhibitors. Clinicians may consider HS-20137 as an effective biologic therapy for sustained disease control.
Conclusion
This phase 2 trial confirms that HS-20137 is effective and safe for treating moderate-to-severe psoriasis in Chinese patients, with durable clinical benefits and improved patient quality of life. These results warrant further development and potential clinical adoption of HS-20137.
References
Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Phase 2 Trial Results
